VEGFA and cardiovascular disorder: Other variables studied, age, sex, duration of CRVO, baseline visual acuity, central subfield thickness, total number of anti-VEGF treatment during the study, longest interval between anti-VEGF treatment during the study, history of cardiovascular disease, history of haematological disease and history of neoplasia at baseline, were all not found to be statistically significant.